Crossmark

Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12885-024-12708-6

Published Online: 2024-08-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Jing

Lv, Pei-Yuan

Zhao, Xiao

Liu, Ming-Lu

Qiu, Lu-Peng

Yang, Zi-Zhong

Sun, Sheng-Jie

Zhang, Guo-Qing
License Information

Text and Data Mining valid from 2024-08-07

Version of Record valid from 2024-08-07
More Information

Article History

Received: 26 March 2024

Accepted: 25 July 2024

First Online: 7 August 2024

Declarations

:

: This study was approved by the ethical review board of the Chinese PLA General Hospital ethics committee (No.S2018-203-01) and was conducted in accordance with the Declaration of Helsinki and local applicable regulatory guidelines.

: All data published here are under the consent for publication. Written informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below